<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03714178</url>
  </required_header>
  <id_info>
    <org_study_id>CS0267</org_study_id>
    <nct_id>NCT03714178</nct_id>
  </id_info>
  <brief_title>A Safety and Feasibility Study of the FARAPULSE Endocardial Ablation System to Treat Paroxysmal Atrial Fibrillation</brief_title>
  <official_title>PEFCAT: A Safety and Feasibility Study of the FARAPULSE Endocardial Ablation System to Treat Paroxysmal Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Farapulse, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Farapulse, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      PEFCAT is a prospective, single-arm, multi-center, safety and feasibility study evaluating&#xD;
      the FARAPULSE Endocardial Ablation System for the treatment of paroxysmal atrial&#xD;
      fibrillation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients undergoing catheter ablation for paroxysmal atrial fibrillation will be screened for&#xD;
      enrollment per protocol inclusion and exclusion criteria. Enrolled patients will then undergo&#xD;
      ablation using the FARAPULSE Endocardial Ablation System. Subjects will be followed at 7&#xD;
      days, 30 days, 75 days, 6 months, and 12 months with a blanking period for recurrent atrial&#xD;
      fibrillation or atrial tachycardia of 3 months following the PEF (pulsed electric field)&#xD;
      catheter ablation procedure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 20, 2018</start_date>
  <completion_date type="Actual">December 21, 2020</completion_date>
  <primary_completion_date type="Actual">December 21, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Patients undergoing catheter ablation of paroxysmal atrial fibrillation and meeting all protocol inclusion/exclusion criteria will be treated with the FARAPULSE Endocardial Ablation System.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary safety endpoint for this study is the Composite Safety Endpoint (CSE) defined as the incidence of early-onset and late-onset serious adverse events (SAEs) which are device- or procedure-related.</measure>
    <time_frame>30 Days</time_frame>
    <description>Early onset (within 30 days of any endocardial ablation for atrial fibrillation). Occurrence of any one of the below events will qualify a subject as a safety failure.&#xD;
Death&#xD;
Myocardial infarction (MI)&#xD;
Persistent diaphragmatic paralysis&#xD;
Stroke or transient ischemic attack (TIA)&#xD;
Peripheral or organ thromboembolism&#xD;
Pericarditis&#xD;
Cardiac tamponade / perforation&#xD;
Vascular access complications&#xD;
Hospitalization (initial or prolonged)*&#xD;
Heart block Late onset (any time during follow-up)&#xD;
Pulmonary vein (PV) stenosis (&gt; 70% diameter reduction from baseline)&#xD;
Atrio-esophageal fistula * Excludes hospitalization (initial &amp; prolonged) solely due to arrhythmia (AF/Atrial Flutter/Atrial Tachycardia) recurrence or due to non-urgent cardioversion (pharmacological or electrical).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feasibility: Pulmonary Vein Isolation</measure>
    <time_frame>1 Day (Acute)</time_frame>
    <description>The proportion of subjects that achieve Acute Procedural Success (APS) defined as the percutaneous endocardial creation of a complete, electrically isolating set of lesions around the ostia of the pulmonary veins (PVI) using the FARAPULSE Endocardial Ablation System during the first procedure, as clinically assessed by entrance and/or exit block performed ≥ 20 minutes after the last PVI lesion is made.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Paroxysmal Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>FARAPULSE Endocardial Ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who are treated with the FARAPULSE Endocardial Ablation System for paroxysmal atrial fibrillation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FARAPULSE Endocardial Ablation System</intervention_name>
    <description>Endocardial ablation using the FARAPULSE Endocardial Ablation System.</description>
    <arm_group_label>FARAPULSE Endocardial Ablation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with documented drug resistant symptomatic PAF who have:&#xD;
&#xD;
               1. Confirmed AF: Documentation may include ECG, transtelephonic monitor (TTM),&#xD;
                  Holter monitor, implanted devices, telemetry strip or similar, recorded within&#xD;
                  one year prior to enrollment and showing at least 30 seconds of AF.&#xD;
&#xD;
               2. Frequent AF, defined as ≥ 2 episodes within 6 months of enrollment.&#xD;
&#xD;
               3. Failed AFD, meaning therapeutic failure of at least one antiarrhythmic drug (AFD;&#xD;
                  class I - IV) for efficacy and / or intolerance&#xD;
&#xD;
          2. Patients who are ≥ 18 and ≤ 75 years of age on the day of enrollment.&#xD;
&#xD;
          3. Patient participation requirements:&#xD;
&#xD;
               1. Lives locally&#xD;
&#xD;
               2. Is willing and capable of providing Informed Consent to undergo study procedures&#xD;
&#xD;
               3. Is willing to participate in all examinations and follow-up visits and tests&#xD;
                  associated with this clinical study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Use of amiodarone within 3 months prior to enrollment&#xD;
&#xD;
          2. Atrial fibrillation that is any of the following&#xD;
&#xD;
               1. Persistent (by diagnosis or duration &gt; 7 days)&#xD;
&#xD;
               2. Secondary to electrolyte imbalance, thyroid disease, alcohol abuse or other&#xD;
                  reversible / non-cardiac causes&#xD;
&#xD;
               3. Requires ≥ 3 cardioversions in the preceding 12 months&#xD;
&#xD;
          3. Cardiac anatomical exclusions by imaging within 3 months prior to enrollment:&#xD;
&#xD;
               1. Left atrial anteroposterior diameter ≥ 5.0 cm as documented by transthoracic&#xD;
                  echocardiography (TTE) or computed tomography (CT)&#xD;
&#xD;
               2. Left ventricular ejection fraction ≤ 40% as documented by TTE&#xD;
&#xD;
          4. Any of the following cardiac procedures, implants or conditions:&#xD;
&#xD;
               1. Clinically significant arrhythmias other than AF&#xD;
&#xD;
               2. Hemodynamically significant valvular disease&#xD;
&#xD;
               3. Prosthetic heart valve&#xD;
&#xD;
               4. NYHA Class III or IV CHF&#xD;
&#xD;
               5. Previous endocardial or epicardial ablation or surgery for AF&#xD;
&#xD;
               6. Atrial or ventricular septal defect closure&#xD;
&#xD;
               7. Atrial myxoma&#xD;
&#xD;
               8. Left atrial appendage device or occlusion&#xD;
&#xD;
               9. Pacemaker, ICD or CRT&#xD;
&#xD;
              10. Significant or symptomatic hypotension&#xD;
&#xD;
              11. Bradycardia or chronotropic incompetence&#xD;
&#xD;
              12. History of pericarditis&#xD;
&#xD;
              13. History of rheumatic fever&#xD;
&#xD;
          5. Any of the following within 3 months of enrollment:&#xD;
&#xD;
               1. Myocardial infarction&#xD;
&#xD;
               2. Unstable angina&#xD;
&#xD;
               3. Percutaneous coronary intervention&#xD;
&#xD;
               4. Heart surgery including coronary artery bypass grafting&#xD;
&#xD;
               5. Heart failure hospitalization&#xD;
&#xD;
               6. Stroke or TIA&#xD;
&#xD;
               7. Clinically significant bleeding&#xD;
&#xD;
               8. Pericarditis or pericardial effusion&#xD;
&#xD;
               9. Left atrial thrombus&#xD;
&#xD;
          6. History of blood clotting or bleeding abnormalities.&#xD;
&#xD;
          7. Contraindication to, or unwillingness to use, systemic anticoagulation&#xD;
&#xD;
          8. Contraindications to CT or MRI&#xD;
&#xD;
          9. Sensitivity to contrast media not controlled by premedication&#xD;
&#xD;
         10. Women of childbearing potential who are pregnant, lactating or not using birth control&#xD;
&#xD;
         11. Serious or untreated medical conditions that would prevent participation in the study,&#xD;
             interfere with assessment or therapy, or confound data or its interpretation,&#xD;
             including but not limited to&#xD;
&#xD;
               1. Solid organ or hematologic transplant, or currently being evaluated for an organ&#xD;
                  transplant&#xD;
&#xD;
               2. Severe lung disease, pulmonary hypertension, or any lung disease involving&#xD;
                  abnormal blood gases or significant dyspnea&#xD;
&#xD;
               3. Chronic renal insufficiency of &lt; 60 mL/min/1.73 m2, any history of renal&#xD;
                  dialysis, or history of renal transplant&#xD;
&#xD;
               4. Active malignancy or history of treated cancer within 24 months of enrollment&#xD;
&#xD;
               5. Clinically significant gastrointestinal problems involving the esophagus, stomach&#xD;
                  and/or untreated acid reflux&#xD;
&#xD;
               6. Clinically significant infection&#xD;
&#xD;
               7. Predicted life expectancy less than one year&#xD;
&#xD;
         12. Clinically significant psychological condition that in the investigator's opinion&#xD;
             would prohibit the subject's ability to meet the protocol requirements&#xD;
&#xD;
         13. Current or anticipated enrollment in any other clinical study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Petr Neuzil, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nemocnice Na Homolce</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nemocnice Na Homolce</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>France</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>October 17, 2018</study_first_submitted>
  <study_first_submitted_qc>October 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2018</study_first_posted>
  <last_update_submitted>February 17, 2021</last_update_submitted>
  <last_update_submitted_qc>February 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>August 22, 2021</submitted>
    <returned>September 17, 2021</returned>
    <submitted>October 24, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

